This Alzheimer's drug reduces symptoms of 30%, says a new study
It is the first drug to successfully slow down the cognitive decline.
Alzheimer's disease is aProgressive neurological disorder This aggravates memory and other cognitive functions over time. However, new research gives scientists and patients hope that the progression of the disease is not an inevitable result. Indeed, a new medication - delivered in the form of weekly infusions twice - appears to reduce Alzheimer's symptoms up to 30% in just 18 months. Researchers are in shock from this breakthrough, which could improve the quality of life of millions of people living with Alzheimer's and world.
"This is a statistically positive result without ambiguity and representsSomething of a historic moment When we see the first convincing modification of Alzheimer's disease, "Rob Howard, PhD, professor of old age psychiatry at the University College London (UCL), saidThe Guardian. "God knows, we waited long enough for that." Read the continuation to find out which medication makes history in dementia research and how it could affect you and your loved ones.
Read this then:Drinking this popular drink reduces the risk of dementia at 38%, the new study says.
This new Alzheimer's drug reduces symptoms by almost 30%.
On September 27, Eisai and Biogen pharmaceutical companiesannounced the results From an 18 -month clinical trial, phase 3 for the Alzheimer Lecanemab medication. Classified as an anti-amyloid antibody treatment, LecaneMab slowed down the cognitive drop rate of 27% in Alzheimer's patients at an early stage, the data has shown.
"This is a historic moment for dementia research, because it is the first phase 3 test of an Alzheimer's drug in a generation to successfully slow down the cognitive decline," saidSusan Kohlhaas, PHD, the director of research at Alzheimer's Research UK. "Many people feel that Alzheimer is an inevitable part of aging. This says: if you intervene early, you can have an impact on the way people are progressing."
Read this then:The nap at this time stimulates the health of your brain, the study says.
The effectiveness of the drug offers clues to Alzheimer's disease.
Beyond the obvious advantages of the drug itself, the experts say that the success of the test also offers indices on the way in whichAlzheimer's disease develops and progresses.
More specifically, it supports "Amyloid hypothesis, "which postulates that" beta-amyloid, a sticky compound that accumulates in the brain, disturbing communication between brain cells and finally killing them "is to blame for Alzheimer's disease." Some researchers believe that defects in the processes governing the production, accumulation or elimination of beta-amyloids is the main cause of Alzheimer, "explains a report by the Alzheimer's association.
Some of the study subjects have experienced side effects.
Although the news of the effectiveness of the drug is undoubtedly promising, the researchers noted that certain subjects of the study underwent side effects following the taking of Lecanemab. In fact, around 21% of trial participants reported undesirable effects, against nine percent of those who take a placebo. These included swelling of the brain or cerebral bleeding visible on pet analyzes. However, only three percent of patients have suffered symptomatic side effects.AE0FCC31AE342FD3A1346EBB1F342FCB
For more health information sent directly to your reception box,Register for our daily newsletter.
The results could open doors to future discoveries.
The trial only lasted 18 months, and the researchers say that given more time, it is possible that the advantages can continue to take effect beyond this period. The National Institute on Health, who has not financed the initial study, says that it is currentlyFinancing of two additional tests which will assess "the safety and efficiency of LecaneMab on participants who have variable quantities of amyloid pathology, but have not yet levels of cognitive decline to justify a diagnosis of dementia". In other words, they will examine whether the drug is able to slow down the rate of cognitive decline in those who have a minimum of symptoms or not at all.
Eisai and Biogen have announced that they plan to request traditional drug approval in the United States by March 2023. Talk to your health care provider to learn more about the interventions and treatments that are currently available for Improve Alzheimer's symptoms.
